

## Rhythm Biosciences secures strategic US platform partnership with Cancer IQ to accelerate geneType™ commercial adoption

### Highlights

- ✓ Rhythm has secured a strategic partnership with Cancer IQ, a leading US digital oncology platform used by over 65 Health Systems encompassing over 345 clinics, providing immediate market access to healthcare providers serving millions of Americans.
- ✓ This partnership creates a clear pathway to recurring test revenues without the cost and complexity of building a direct sales force, significantly de-risking Rhythm's US commercialisation strategy.
- ✓ The integration enables streamlined ordering with automated data population, eliminating paperwork barriers that typically slow clinical adoption and supporting scalable commercial uptake in the US.
- ✓ Positions Rhythm to expand recurring test volumes through embedded clinical workflows, with the platform designed to support repeat testing as patients move through cancer screening pathways.

**Melbourne, Australia, 28th January 2026:** Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce that it has entered into a strategic partnership with CancerIQ, a leading US-based digital healthcare technology platform that helps hospitals and healthcare providers scale their high risk genetic testing programs through workflow optimisation, automation of test ordering, and continuous process improvement.

By partnering with an established platform already deployed across major US health systems, Rhythm avoids the costly and time-consuming process of building hospital relationships. This accelerates the Company's path to revenue while reducing capital requirements, a significant commercial advantage in the competitive cancer diagnostics market.

CancerIQ's ([www.canceriq.com](http://www.canceriq.com)) cloud-based platform is currently used by more than 65 US health systems and over 345 clinics. Under the partnership, Rhythm's geneType™ Cancer Risk Assessment will be available within the CancerIQ workflow, enabling healthcare providers to seamlessly order geneType™ tests with automated patient data population. CancerIQ's ordering wizard (1) reduces administrative friction that typically slows adoption, (2) improves clinical efficiency and (3) supports scalable commercial rollout of vendors like geneType™ across the US healthcare system.

Rhythm's geneType™ Multi-Test Risk Assessment expands the menu of option on the CancerIQ platform by adding polygenic and multifactor risk modelling alongside the hereditary and multi-gene testing solutions already available through CancerIQ. While hereditary testing often helps only identify individuals with rare, high-impact genetic mutations, geneType™ evaluates the combined influence of common genetic variants together with clinical and lifestyle factors to estimate a patient's overall baseline risk. Within the platform, geneType™ stands out for its integrated approach to combining genetic, clinical, and modifiable risk inputs into a single risk model designed to support more personalized screening and prevention planning.

By embedding geneType™ within CancerIQ's clinical infrastructure, Rhythm gains a distribution channel aligned with recurring clinical workflows. Each test ordered through the platform generates revenue for Rhythm, with the embedded workflow designed to support repeat test volumes as patients move through cancer screening pathways, providing a foundation for long-term commercial traction in the US market.

CancerIQ's health system partners include CancerIQ's health system partners include Advocate Health, Fred Hutch Cancer Center, Mount Sinai Health System, and University of Pittsburgh Medical Center. More recently, CancerIQ has expanded through enterprise-wide master service agreements with Ardent Health, Ascension, CommonSpirit Health, Corewell Health, and Hackensack Meridian Health, reflecting the platform's strong penetration in key US healthcare regions. These partnerships provide third-party validation of the platform's clinical utility and market acceptance.

The partnership aligns with Rhythm's strategy to embed geneType™ into established clinical platforms that support scalable deployment across large healthcare networks. The integration model enables

efficient market access while leveraging CancerIQ's existing provider relationships, workflow infrastructure and data capabilities, minimising Rhythm's go-to-market execution risk.

The US remains one of the world's largest precision medicine and preventative healthcare markets, with growing demand for personalised risk assessment tools. The CancerIQ partnership strengthens Rhythm's commercial footprint in this market and supports broader adoption of geneType™ as healthcare providers increasingly seek comprehensive genomic risk assessment solutions.

**Rhythm CEO & MD Dr. David Atkins said** "This partnership transforms our US market entry strategy. Instead of building clinic relationships one-by-one, we now have immediate access to hundreds of clinics through a proven platform that's already trusted by leading health systems. More importantly, we're embedded in the clinical workflow where cancer risk decisions are made daily - this is exactly how successful diagnostic tests achieve sustainable, recurring revenues."

**CancerIQ Founder and CEO Feyi Ayodele commented** "Our mission is to help health systems scale access to genomics and innovation across oncology by embedding risk assessment directly into clinical workflows. Integrating geneType™ into the CancerIQ platform expands our ability to identify cancer risk earlier and at a population level, extending beyond traditional hereditary testing. This partnership reinforces CancerIQ's role as a scalable infrastructure layer for precision diagnostics, enabling providers to operationalize emerging technologies within a single, unified platform."

- ENDS -

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).**

#### **About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

#### **About ColoSTAT®**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

#### **About geneType™**

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping



individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genotype.com](http://www.genotype.com).

#### **About CancerIQ**

CancerIQ is the only cancer-focused precision health platform that empowers healthcare providers to detect cancer earlier and prevent it altogether across all patient populations. Integrated directly into real-time EHR workflows, CancerIQ makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, cutting-edge clinical solutions, and genomic innovations. Learn more at [canceriq.com](http://canceriq.com) and follow CancerIQ on [LinkedIn](#).

For personal use only